Marie-Laure Chaix 1 , 2 , Isabelle Charreau 3 , Claire Pintado 4 , Constance Delaugerre 1 , 2 , Nadia Mahjoub 1 , Laurent Cotte 5 , Catherine Capitant 3 , François Raffi 6 , Eric Cua 7 , Gilles Pialoux 8 , Cécile Tremblay 9 , Laurence Meyer 3 , 10 , Jean-Michel Molina 2 , 4 , ANRS IPERGAY Study Group
08 November 2018
We evaluated the impact of on-demand oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) on herpes simplex virus (HSV)-1/2 incidence among men who have sex with men (MSM) enrolled in the ANRS IPERGAY trial. Serum samples were tested at baseline and at the last visit for HSV-1/2 antibodies. Overall HSV-1 incidence was 11.7 per 100 person-years; 16.2 and 7.8 per 100 person-years in the TDF/FTC and placebo arm, respectively ( P = .19). Overall HSV-2 incidence was 7.6 per 100 person-years; 8.1 and 7.0 per 100 person-years in the TDF/FTC and placebo arm, respectively ( P = .75). On-demand oral PrEP with TDF/FTC failed to reduce HSV-1/2 incidence in this population.